Aspirus Cancer Care is offering a new type of immunotherapy treatment that has emerged as one of the most promising strategies for battling certain types of cancer including Lymphoma, Acute …
This item is available in full to subscribers.
To continue reading, you will need to either log in, using the login form, below, or purchase a new subscription.
If you are a current print subscriber, you can set up a free website account and connect your subscription to it by clicking here.
Otherwise, click here to view your options for subscribing.
Please log in to continue |
Aspirus Cancer Care is offering a new type of immunotherapy treatment that has emerged as one of the most promising strategies for battling certain types of cancer including Lymphoma, Acute Lymphocytic Leukemia (ALL), multiple myeloma, and small-cell lung cancer.
Bispecific T-cell Engager (BiTE) Therapy is a type of immunotherapy that triggers a patient’s own immune system to attack cancer cells. BiTE Therapy essentially directs certain immune cells, called T-cells, to attack and kill cancer cells.
Dr. Thomas Oliver, an Oncologist and Hematologist for Aspirus Cancer Care, explains how this innovative treatment works. “BiTEs offer targeted therapy by using antibodies to connect cancer cells and immune T-cells. The T-cell’s antitumor functions are stimulated and molecules that poke holes in the cancer cells are released,” Oliver says.
One of many benefits of BiTEs is the ability to target tumors directly while minimizing damage to healthy tissues. “While patients undergoing BiTE Therapy may experience side effects, they differ from the side effects patients typically have to endure with chemotherapy,” continues Oliver.
Patients undergoing treatment for Lymphoma, ALL, multiple myeloma, and small-cell lung cancer should discuss with their provider whether BiTE Therapy is right for them.
Aspirus Cancer Care includes a comprehensive team of experts to compassionately care for cancer patients along their entire treatment journey, including nurse navigators, pharmacists, social workers, dieticians, and more.
To learn more, visit aspirus.org/cancer.